While all the underlying mechanisms of resistance to venetoclax in CLL have yet to be elucidated, the discovery that acquisition of the G101V mutation in BCL-2, greatly reducing its affinity for venetoclax, could pre-date and lead to clinical disease progression in some patients was an important breakthrough85. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.